Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis

JAMA Neurology

Volumn 71, Issue 5, 2014, Pages 575-580

  Liew, Wendy K M ^a   Powell, Christine A ^a   Sloan, Steven R ^a,b   Shamberger, Robert C ^a   Weldon, Christopher B ^a   Darras, Basil T ^a   Kang, Peter B ^a,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PYRIDOSTIGMINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; EYE DISEASE; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFANT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THYMECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MYASTHENIA GRAVIS; PLASMAPHERESIS; PYRIDOSTIGMINE BROMIDE; RETROSPECTIVE STUDIES;

EID: 84900514583     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.17     Document Type: Article

References (33)

1. Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology. 2000;107(3):504-510.
2. Lindstrom JM, SeyboldME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value: 1975. Neurology. 1998; 51(4):933-939.
3. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365-368.
4. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol. 2005;18(5):519-525.
5. Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve. 2009;39(4):423-431.
6. Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. J Neurol Neurosurg Psychiatry. 2007;78(4):417-418.
7. Zhang X, YangM, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2007;78(4):386-390.
8. Andrews PI, Massey JM, Howard JF Jr, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology. 1994;44(7):1208-1214.
9. Andrews PI, Massey JM, Sanders DB. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology. 1993;43(5):977-982.
10. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibodynegativemyasthenia gravis. J Neurol. 2012;259(3):427-435.
11. Barth D, Nabavi NouriM, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017- 2023.
12. Evoli A, Batocchi AP, Bartoccioni E, Lino MM, Minisci C, Tonali P. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord. 1998;8(8):561-567.
13. PittM. Neurophysiological strategies for the diagnosis of disorders of the neuromuscular junction in children. Dev Med Child Neurol. 2008;50(5):328-333.
14. Tracy MM, McRaeW, Millichap JG. Graded response to thymectomy in children with myasthenia gravis. J Child Neurol. 2009;24(4):454-459.
15. Millichap JG, Dodge PR. Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients. Neurology. 1960;10:1007-1014.
16. SeyboldME, Baergen RN, Nave B, Lindstrom JM. Anti-acetylcholine-receptor antibody concentrations after thymectomy in patients with myasthenia gravis. Br Med J. 1978;2(6144):1051- 1053.
17. Snead OC III, Benton JW, Dwyer D, et al. Juvenile myasthenia gravis. Neurology. 1980;30(7, pt 1):732-739.
18. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837-841.
19. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin formyasthenia gravis. Cochrane Database Syst Rev. 2008;(1):CD002277.
20. McMillan HJ, Darras BT, Kang PB. Autoimmune neuromuscular disorders in childhood. Curr Treat Options Neurol. 2011;13(6):590-607.
21. Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand. 2006;114(2):119-123.
22. Kaminski HJ, Cutter G, Ruff R. Practice parameters and focusing research: plasma exchange formyasthenia gravis. Muscle Nerve. 2011;43(5):625-626.
23. Selcen D, Dabrowski ER,Michon AM, NigroMA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22(1):40-43.
24. Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used formyasthenia gravis. Ann Neurol. 2010;68(6):797-805.
25. Miller RG, Barohn RJ, Dubinsky R. Expanding the evidence base for therapeutics inmyasthenia gravis. Ann Neurol. 2010;68(6):776-777.
26. Mandawat A, Mandawat A, Kaminski HJ, Shaker ZA, Alawi AA, Alshekhlee A. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve. 2011;43(4):578-584.
27. Skeie GO, Apostolski S, Evoli A, et al; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893-902.
28. Bril V, Barnett-Tapia C, Barth D, Katzberg HD. IVIG and PLEX in the treatment of myasthenia gravis. Ann N Y Acad Sci. 2012;1275:1-6.
29. Adams C, Theodorescu D, Murphy EG, Shandling B. Thymectomy in juvenile myasthenia gravis. J Child Neurol. 1990;5(3):215-218.
30. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7-15.
31. Rodriguez M, Gomez MR, Howard FMJr, Taylor WF.Myasthenia gravis in children: long-term follow-up. Ann Neurol. 1983;13(5):504-510.
32. Gadient P, Bolton J, Puri V. Juvenile myasthenia gravis: three case reports and a literature review. J Child Neurol. 2009;24(5):584-590.
33. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: disease severity and prognosis. Acta Neurol Scand Suppl. 2006;183:24-25.